learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research CAQ Corner: Basic Concepts of Transplant Immunology
The document explains how the immune system reacts to organ transplants and the treatments used to prevent rejection.
research Long-Term Outcome After Hand and Forearm Transplantation: A Retrospective Study
Hand and forearm transplants can be successful long-term, but they come with challenges like rejection and side effects from immunosuppression.
research Transplantation Immunology: Solid Organ and Bone Marrow
Transplant success has improved with better immunosuppressive drugs and donor matching.
research Viral-Associated Trichodysplasia of Immunosuppression
A 5-year-old boy's skin condition improved with systemic valganciclovir after a cardiac transplant and immunosuppressive therapy.
research Local Heroes or Villains: Tissue-Resident Memory T Cells in Human Health and Disease
Tissue-resident memory T cells can protect against infections and cancer but may also contribute to autoimmune diseases.
Community Join
5 / 38 resultscommunity HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community Fin/dut increase in estrogen and autoimmune diseases
The conversation discusses the link between increased estrogen and autoimmune diseases, with a focus on avoiding soy and milk. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
community Residents of Victoria, Australia, sign up for a monoclonal antibody clinical trial – potential cure
A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community Somebody has gotta try this- HMI-115 reference anti-body
The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.